Scancell Holdings plc (SCNLF) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Scancell Holdings plc (SCNLF) Healthcare & Pipeline Overview

Scancell Holdings plc is a clinical-stage biopharmaceutical company based in Oxford, UK, specializing in the development of innovative ImmunoBody® and Moditope® platform-based vaccines and antibody treatments for cancer and infectious diseases, addressing critical unmet medical needs within the global healthcare sector.

What Is the Investment Thesis for SCNLF?

Scancell Holdings plc presents an investment thesis centered on its innovative ImmunoBody® and Moditope® immunotherapy platforms, which underpin a diverse clinical-stage pipeline targeting significant unmet medical needs in oncology and infectious diseases. With a market capitalization of $140M, the company is advancing multiple candidates, including SCIB1 for metastatic melanoma, SCIB2/iSCIB2 for solid tumors, and Modi-1 for various advanced cancers, with Modi-1 currently in Phase I/II trials. The development of SCOV1 and SCOV2 COVIDITY DNA vaccines also demonstrates platform versatility. Key value drivers include successful progression through clinical trial phases, which could validate its proprietary technologies and attract strategic partnerships or licensing agreements. However, as a clinical-stage biotech with a profit margin of -117.0%, the company faces inherent risks associated with R&D success rates, regulatory approvals, and ongoing funding requirements. Its OTC Other listing also implies lower liquidity and less stringent disclosure compared to major exchanges. Future funding announcements and clinical data readouts, particularly for Modi-1, will be critical catalysts for potential valuation shifts.

Based on FMP financials and quantitative analysis

SCNLF Key Highlights

Scancell Holdings plc maintains a gross margin of 78.5%, indicating strong control over its cost of goods sold, despite being a clinical-stage company with no commercial products.

• The company operates with a profit margin of -117.0%, reflecting significant ongoing research and development expenses typical for a biopharmaceutical firm in the clinical development phase.
• With a market capitalization of $140M, Scancell Holdings plc is positioned as a small-cap biotechnology company, highlighting its growth potential and inherent risks.
• The company's Beta of 0.71 suggests lower volatility compared to the broader market, indicating a potentially more stable stock performance relative to market fluctuations.
• Scancell Holdings plc currently has no dividend yield, which is common for clinical-stage biotechnology companies that typically reinvest earnings into research and pipeline development.

Who Are SCNLF's Competitors?

SCNLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SCNLF's Key Strengths?

Proprietary and innovative ImmunoBody® and Moditope® technology platforms for immunotherapy development.

• Diverse clinical pipeline addressing multiple significant unmet medical needs in oncology (melanoma, solid tumors, various advanced cancers) and infectious diseases (COVID-19).
• Strong gross margin of 78.5% indicates efficient R&D cost management for its stage.
• Experienced leadership in CEO Phillip John L'Huillier, overseeing a focused team of 61 employees.
• Headquartered in Oxford, UK, a hub for biotechnology research and talent.

What Are SCNLF's Weaknesses?

Operating at a significant loss with a profit margin of -117.0%, typical for clinical-stage biotechs but indicating reliance on external funding.

• No commercialized products, making the company entirely dependent on successful clinical trial outcomes and regulatory approvals.
• Trades on the OTC market ('OTC Other'), which typically implies lower liquidity, less stringent disclosure requirements, and potentially higher price volatility.
• High capital requirements for ongoing research, development, and clinical trials.
• Relatively small employee base (61 employees) for a company with a diverse pipeline, potentially limiting the pace of simultaneous development.

What Could Drive SCNLF Stock Higher?

SCNLF catalyst: Announcement of Phase I/II clinical trial results for Modi-1 in head and neck, triple-negative breast, ovarian, and renal cancers, expected to provide critical efficacy and safety data.

• Progression of SCIB1 into later-stage clinical trials for metastatic melanoma, signaling advancement towards potential regulatory approval.
• Initiation of new clinical trials or expansion of existing trials for SCIB2/iSCIB2 into additional solid tumor indications, broadening market potential.
• Development updates on Modi-2, targeting homocitrullinated cancer antigens, which could highlight novel therapeutic approaches.
• Potential strategic partnerships or licensing agreements for any of its platform technologies or pipeline assets, which could provide non-dilutive funding or accelerate development.

What Are the Key Risks for SCNLF?

Financial-distress signal — its Altman Z-Score of -12.27 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected adverse events for any of its pipeline candidates (SCIB1, SCIB2/iSCIB2, Modi-1, Modi-2), which could lead to significant delays or termination of development programs.
• Significant capital requirements for continued research and development, clinical trials, and operational expenses, necessitating future funding rounds which could dilute existing shareholders.
• Intense competition within the biotechnology sector, particularly in oncology and immunotherapy, from larger pharmaceutical companies with greater resources and established market presence.
• Regulatory hurdles and the lengthy, complex approval processes for novel biopharmaceutical products, which could delay market entry or result in non-approval.
• The inherent risks associated with an 'OTC Other' listing, including lower liquidity, reduced transparency due to 'Unknown' disclosure status, and potential for increased price volatility.

What Are the Growth Opportunities for SCNLF?

• **Advancement of SCIB1 for Metastatic Melanoma:** The successful progression and potential approval of SCIB1, an ImmunoBody® cancer vaccine for metastatic melanoma, represents a significant growth opportunity. Metastatic melanoma is a severe cancer with high unmet needs, and effective new treatments can capture substantial market share. The global melanoma therapeutics market is projected to reach several billion dollars in the coming years, driven by increasing incidence and demand for innovative therapies. Positive clinical trial results and regulatory milestones for SCIB1 would validate Scancell's ImmunoBody® platform and open pathways for commercialization or strategic partnerships, potentially within a 3-5 year timeframe.
• **Expansion of SCIB2/iSCIB2 into Solid Tumors:** The evaluation of SCIB2/iSCIB2 against various solid tumors, including non-small cell lung cancer (NSCLC), offers a broad growth avenue. Solid tumors represent a vast market, with NSCLC alone being one of the most prevalent and deadly cancers globally. Successful clinical development in these indications would significantly expand Scancell's addressable market beyond melanoma. The global lung cancer therapeutics market is valued in the tens of billions of dollars and continues to grow. Demonstrating efficacy in multiple solid tumor types would showcase the versatility of the ImmunoBody® platform, attracting further investment and partnership opportunities over the next 5-7 years.
• **Clinical Success of Modi-1 in Multiple Cancers:** Modi-1, currently in Phase I/II clinical trials for head and neck, triple-negative breast, ovarian, and renal cancers, targets highly challenging and often aggressive malignancies with limited treatment options. Success in these trials would position Modi-1 as a potential breakthrough therapy. The markets for these specific cancer types collectively represent multi-billion dollar opportunities. Positive data from these trials would be a strong validation of Scancell's Moditope® platform, potentially leading to accelerated development pathways and significant commercial value within a 4-6 year horizon.
• **Development of Modi-2 for Homocitrullinated Antigens:** The ongoing work on Modi-2, designed to target homocitrullinated cancer antigens, represents a novel and potentially highly specific approach to cancer immunotherapy. This platform could unlock treatments for cancer types where these specific antigens are prevalent, offering a differentiated therapeutic strategy. While still in earlier stages, the ability to target unique cancer antigens could lead to highly effective and personalized treatments, addressing niche but significant patient populations. This innovation could provide long-term growth potential and intellectual property advantages, with market impact likely beyond a 7-year timeframe.
• **Leveraging COVIDITY DNA Vaccines for Infectious Diseases:** The development of SCOV1 and SCOV2 COVIDITY DNA vaccines against SARS-CoV-2 demonstrates Scancell's capability to apply its platform technology to infectious diseases. While the immediate COVID-19 vaccine market may be saturated, this capability positions Scancell to respond to future pandemic threats or develop vaccines for other infectious diseases with high unmet needs. The global vaccine market is a multi-billion dollar industry, and having a proven platform for rapid vaccine development could open new revenue streams and strategic collaborations in the infectious disease space, offering growth opportunities over the next 5-10 years.

What Threats Does SCNLF Face?

• Clinical trial failures or unexpected adverse events, leading to delays or discontinuation of drug candidates.
• Intense competition from other biotechnology and pharmaceutical companies developing similar or superior immunotherapies.
• Stringent and evolving regulatory hurdles, potentially delaying or preventing market approval.
• Challenges in securing adequate funding for ongoing R&D and clinical operations.
• Market acceptance and reimbursement challenges for novel therapies, even if approved.

What Are SCNLF's Competitive Advantages?

• Proprietary ImmunoBody® and Moditope® technology platforms for vaccine and antibody development.
• Extensive intellectual property portfolio surrounding its novel drug candidates and delivery mechanisms.
• Specialized scientific expertise and clinical development experience in oncology and immunology.
• Clinical data generated from ongoing trials, which, if positive, can create significant barriers to entry for competitors.
• Focus on specific, challenging cancer antigens and disease areas with high unmet medical needs.

What Does SCNLF Do?

Scancell Holdings plc, founded in 1997 and headquartered in Oxford, United Kingdom, is a biopharmaceutical company operating in the clinical development stage. The company's core mission is to innovate and bring to market novel vaccines and antibody-based treatments, specifically targeting significant unmet medical needs across both oncology and infectious diseases. Scancell's strategic approach involves leveraging its proprietary technology platforms to stimulate the body's immune system to combat disease. A key product in its pipeline is SCIB1, an ImmunoBody® cancer vaccine engineered for the treatment of metastatic melanoma, a severe form of skin cancer. Expanding its oncology focus, the company is also developing the SCIB2/iSCIB2 vaccine, which is currently undergoing evaluation for its efficacy against various solid tumors, including non-small cell lung cancer. Further diversifying its cancer immunotherapy portfolio, Scancell is advancing Modi-1 through Phase I/II clinical trials. This treatment targets a range of challenging cancers such as head and neck, triple-negative breast, ovarian, and renal cancers. Additionally, the company is working on Modi-2, a therapy designed to specifically target homocitrullinated cancer antigens, representing another innovative approach to cancer treatment. Beyond oncology, Scancell has also applied its expertise to infectious diseases, developing SCOV1 and SCOV2 COVIDITY, which are DNA vaccines aimed at combating the SARS-CoV-2 virus. As a clinical-stage entity, Scancell Holdings plc is dedicated to progressing its pipeline through rigorous clinical trials, aiming to ultimately provide transformative therapeutic options to patients worldwide.

What Products and Services Does SCNLF Offer?

• Develops novel vaccines and antibody-based treatments for cancer and infectious diseases.
• Utilizes proprietary ImmunoBody® platform for cancer vaccine development.
• Leverages Moditope® platform for targeted cancer immunotherapies.
• Has SCIB1, an ImmunoBody® cancer vaccine, in development for metastatic melanoma.
• Is evaluating SCIB2/iSCIB2 vaccine for various solid tumors, including non-small cell lung cancer.
• Advancing Modi-1 through Phase I/II clinical trials for head and neck, triple-negative breast, ovarian, and renal cancers.
• Working on Modi-2, designed to target homocitrullinated cancer antigens.
• Developing SCOV1 and SCOV2 COVIDITY DNA vaccines for the SARS-CoV-2 virus.

How Does SCNLF Make Money?

• Primarily focused on research and development (R&D) of clinical-stage biopharmaceutical products.
• Seeks to generate revenue through potential licensing agreements, partnerships, or eventual commercialization of approved therapies.
• Relies on equity financing, grants, and collaborations to fund extensive clinical trials and R&D activities.
• Aims to create intellectual property through novel platforms and drug candidates, which can be monetized through various strategic avenues.
• Operates as a pre-revenue company, with significant investment in pipeline development prior to market entry.

What Industry Does SCNLF Operate In?

Scancell Holdings plc operates within the dynamic and highly innovative Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by intensive research and development efforts aimed at discovering, developing, and commercializing novel biological products and therapies. The global biotechnology market is experiencing robust growth, driven by advancements in genomics, personalized medicine, and immunotherapies, with a strong focus on oncology and infectious diseases. Scancell's positioning is specifically within the immunotherapy segment, a rapidly expanding area where treatments harness the body's own immune system to fight diseases like cancer. The competitive landscape is intense, featuring numerous large pharmaceutical companies and smaller biotech firms vying for market share and intellectual property. Scancell distinguishes itself through its proprietary ImmunoBody® and Moditope® platforms, which aim to offer differentiated mechanisms of action for vaccine and antibody development. As a clinical-stage company, Scancell is currently in the pre-commercialization phase, focusing on advancing its pipeline through clinical trials to demonstrate efficacy and safety, a critical step for market entry and competitive standing.

Who Are SCNLF's Key Customers?

• Ultimately, patients suffering from cancers like metastatic melanoma, solid tumors, head and neck, triple-negative breast, ovarian, and renal cancers.
• Healthcare providers and oncologists who would prescribe and administer the company's approved therapies.
• Potential pharmaceutical partners interested in licensing, co-developing, or acquiring rights to Scancell's drug candidates or platforms.
• Governments and public health organizations for infectious disease vaccines like COVIDITY.

Company Profile

Scancell Holdings plc operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Oxford, GB. The company is led by CEO Phillip John L'Huillier. SCNLF has traded publicly since 2013.

Scancell Holdings plc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.27 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Scancell Holdings plc stands at 90.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.56 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -5.5%, the inverse of the P/E and a quick read on earnings relative to price.

SCNLF Valuation & Market Position

With a $140M market cap, Scancell Holdings plc sits in the micro-cap segment of the market. Relative to its peer group, SCNLF's quantitative score of 54/100 is below the peer average of 76/100.

Wall Street analysts project Scancell Holdings plc revenue of about $835K for fiscal 2026, with EPS near $-0.01.

SCNLF Financials

SCNLF Latest News

No recent news available for SCNLF.

SCNLF Analyst Consensus

SCNLF MoonshotScore

SCNLF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources